Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference

Rhea-AI Summary

Sensei Biotherapeutics (Nasdaq: SNSE) announced its participation in a panel discussion titled ‘Overcoming Resistance & Immunosuppression in Solid Tumors’ at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 20, 2023, at 3:00 p.m. ET. The company specializes in developing next-generation therapeutics for cancer patients through its TMAb™ platform.

Sensei's lead candidate is SNS-101, designed to inhibit T cell suppression in the tumor microenvironment. The company is also advancing SNS-102, targeting VSIG-4, and SNS-103, which targets ENTPDase1, also known as CD39. For more information, visit www.senseibio.com.

BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in a panel titled ‘Overcoming Resistance & Immunosuppression in Solid Tumors’ at Canaccord Genuity’s Horizons in Oncology Virtual Conference on Thursday, April 20^th at 3:00 p.m. ET.

About Sensei Biotherapeutics
Sensei Biotherapeutics (Nasdaq: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.

Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
mbiega@senseibio.com

Media Contact:
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com

FAQ

What event will Sensei Biotherapeutics participate in on April 20, 2023?

Sensei Biotherapeutics will participate in a panel titled ‘Overcoming Resistance & Immunosuppression in Solid Tumors’ at the Canaccord Genuity Horizons in Oncology Virtual Conference.

What is the focus of Sensei Biotherapeutics?

Sensei Biotherapeutics focuses on the discovery and development of next-generation therapeutics for cancer patients, utilizing its TMAb™ platform.

What is SNS-101 developed by Sensei Biotherapeutics?

SNS-101 is Sensei Biotherapeutics' lead investigational candidate, designed to block the VISTA checkpoint selectively within the tumor microenvironment.

What are the other investigational candidates from Sensei Biotherapeutics?

In addition to SNS-101, Sensei is developing SNS-102, targeting VSIG-4, and SNS-103, targeting ENTPDase1.

What is the stock symbol for Sensei Biotherapeutics?

The stock symbol for Sensei Biotherapeutics is SNSE.